IDM Obtains Its First Japanese Patent.Business Editors/Health/Medical Writers
PARIS--(BUSINESS WIRE)--June 2, 2003
IDM (1) See identity management.
(2) (Integrated Device Manufacturer) A company that performs every step of the chip-making process, including design, manufacture, test and packaging. Examples of IDMs are Intel, AMD, Motorola, IBM, TI and Lucent. (Immuno-Designed Molecules), a biopharmaceutical company specialized in cellular immunotherapy, has been issued its first Japanese patent (Japan No. 541 583).
This patent, called "New antigen presenting cells, a process for preparing the same and their use as cellular vaccines" covers the preparation and use of Dendritophages(R) for therapeutic anti-cancer vaccination.
Dendritophages are one of the two families of immune therapy products called Cell Drugs developed by IDM against cancer. Dendritophages are experimental therapeutic vaccines, produced from dendritic cells loaded with tumor antigens. Studies are in progress to assess their ability to prevent the recurrence of certain cancers.
The IDM product portfolio includes Phase II therapeutic vaccines for prostate cancer prostate cancer, cancer originating in the prostate gland. Prostate cancer is the leading malignancy in men in the United States and is second only to lung cancer as a cause of cancer death in men. and melanoma.
IDM was already issued this patent in Australia. It is pending in Canada and in Europe and will probably be authorized soon in the USA.
The IDM portfolio includes 78 issued patents (including 18 in the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. ) and 91 pending patent applications (including 22 in the United States).
Jean-Loup Romet-Lemonne, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of IDM notes: "Given the length of the procedures at the Japanese patent office, we are especially pleased to obtain this first patent. It will reinforce the attraction of IDM for partnerships with Japanese companies."
IDM - The Immunogenics Company(R)
IDM is a leading biopharmaceutical company developing a new family of immunotherapy products called Cell Drugs to fight cancer and other life-threatening diseases. IDM applies its proprietary technologies to selectively isolate, engineer, expand and activate specific cell populations which are involved in therapeutic vaccination. The Company's products are designed to boost the immune system immune system
Cells, cell products, organs, and structures of the body involved in the detection and destruction of foreign invaders, such as bacteria, viruses, and cancer cells. Immunity is based on the system's ability to launch a defense against such invaders. , destroy residual tumor cells, and immunize im·mu·nize
1. To render immune.
2. To produce immunity in, as by inoculation.
im patients to prevent tumor recurrence. IDM's most advanced product is in Phase III for the treatment of ovarian cancer ovarian cancer
Malignant tumour of the ovaries. Risk factors include early age of first menstruation (before age 12), late onset of menopause (after age 52), absence of pregnancy, presence of specific genetic mutations, use of fertility drugs, and personal history of breast .
For more information, please visit IDM's Web site, http://www.idm-biotech.com.